Aptevo Therapeutics (NASDAQ:APVO) Trading Up 5.6%

Aptevo Therapeutics Inc (NASDAQ:APVO) was up 5.6% on Thursday . The stock traded as high as $1.02 and last traded at $0.94, approximately 1,574,994 shares traded hands during mid-day trading. An increase of 183% from the average daily volume of 556,810 shares. The stock had previously closed at $0.89.

Several equities analysts have recently weighed in on APVO shares. Roth Capital reaffirmed a “buy” rating on shares of Aptevo Therapeutics in a research note on Thursday, May 23rd. Zacks Investment Research lowered Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Piper Jaffray Companies lifted their price objective on Aptevo Therapeutics from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Aptevo Therapeutics currently has an average rating of “Buy” and a consensus target price of $7.88.

The company has a market cap of $40.13 million, a price-to-earnings ratio of -0.39 and a beta of 2.39. The company has a quick ratio of 2.91, a current ratio of 3.15 and a debt-to-equity ratio of 0.60. The firm’s fifty day moving average price is $0.88.

Aptevo Therapeutics (NASDAQ:APVO) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44). The business had revenue of $7.02 million for the quarter, compared to the consensus estimate of $6.30 million. Aptevo Therapeutics had a negative return on equity of 122.33% and a negative net margin of 199.24%. As a group, equities research analysts forecast that Aptevo Therapeutics Inc will post -1.4 earnings per share for the current year.

In related news, Director Zsolt Harsanyi bought 50,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were acquired at an average cost of $0.78 per share, for a total transaction of $39,000.00. Following the acquisition, the director now owns 50,000 shares in the company, valued at approximately $39,000. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Fuad El-Hibri bought 30,000 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The shares were bought at an average price of $0.89 per share, for a total transaction of $26,700.00. Following the completion of the acquisition, the director now owns 959,521 shares in the company, valued at approximately $853,973.69. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 326,380 shares of company stock worth $271,844. Company insiders own 11.74% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its holdings in Aptevo Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,049 shares of the biotechnology company’s stock worth $1,831,000 after purchasing an additional 16,482 shares during the last quarter. Deutsche Bank AG increased its holdings in Aptevo Therapeutics by 251.7% during the 4th quarter. Deutsche Bank AG now owns 330,200 shares of the biotechnology company’s stock worth $419,000 after purchasing an additional 236,300 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Aptevo Therapeutics during the 1st quarter worth approximately $33,000. Institutional investors own 36.37% of the company’s stock.

About Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Read More: Diversification For Individual Investors

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.